GRI Bio has announced positive topline results from its phase 2a clinical trial evaluating GRI-0621 in idiopathic pulmonary ...

Genfit has announced encouraging preliminary results from its phase 1b clinical trial evaluating investigational drug GNS561 in combination with a MEK inhibitor (MEKi) in patients with KRAS mutated ...

Johnson & Johnson has reported groundbreaking results from the phase 3 MajesTEC-3 study, highlighting the potential of ...

Modus Therapeutics Holding AB has announced that the first patient has been dosed in part 2 of its ongoing phase 2a clinical study evaluating sevuparin for the treatment of chronic kidney disease (CKD ...

Enterprise Therapeutics has announced the publication of results from its phase 1 study of ETD001, a long-acting inhaled ...

Steven Pipe, Professor of Pediatrics and Pathology at the University of Michigan, explained: “The five-year HOPE-B results ...

Johnson & Johnson has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Rybrevant (amivantamab) in combination with carboplatin and pemetrexed for use within NHS Scotland as a ...

Johnson & Johnson has received European Commission approval for nipocalimab, marketed as IMAAVY, as an add-on therapy for ...

Bayer’s ASSESS study is a randomised, double-blind, placebo-controlled, parallel group phase 2a trial with an extension phase ...

Pharvaris has announced positive topline data from its RAPIDe-3 pivotal phase 3 study, confirming the potential of ...

The phase 1 trial, VNA-318-01, was a randomized, double-blind study involving 92 healthy male subjects. Interim results ...

Johnson & Johnson has announced updated results from the phase 3 CARTITUDE-4 study, showing that CARVYKTI (ciltacabtagene autoleucel; cilta-cel) can deliver durable treatment-free remissions as early ...